stockrow
Saturday 7 November 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
9.54
0.17
+1.81%
Follow SNDX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.56 | 9.49 | 7.72 | 5.83 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.19) | (40.95) | (64.26) | (61.94) | |
P/B ratio |
28.16 | 49.53 | 128.84 | 0.00 | |
Price to Tangible BV |
28.16 | 49.53 | 128.84 | 0.00 | |
EV/Sales |
10.29 | 9.52 | 7.94 | 6.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.49) | (7.43) | (9.07) | (10.50) | |
EV/FCF |
(5.49) | (7.43) | (9.06) | (10.49) | |
Quick Ratio |
4.01 | 4.88 | 6.26 | 4.25 | |
Current Ratio |
4.40 | 5.47 | 6.77 | 4.69 | |
Net Debt/EBITDA |
1.09 | 0.50 | (0.84) | (3.49) | |
Debt/Assets |
64.92% | 72.77% | 83.58% | 84.93% | |
Debt/Equity |
5.32 | 8.26 | 38.95 | (34.24) | |
Asset Turnover |
0.27 | 0.39 | 0.39 | 0.47 | |
Operating CF/Net income |
1.02 | 1.18 | 0.61 | 0.55 | |
Capex/Depreciation |
0.04 | 0.00 | 0.08 | 0.00 | |
Interest Coverage |
(5.75) | (2.89) | (3.16) | (3.23) | |
Research and Development Expense of Revenue |
114.84% | 90.72% | 93.47% | 81.01% | |
Selling, General and Administrative Expense of Revenue |
72.91% | 57.95% | 57.07% | 52.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
16.43% | 18.58% | 19.25% | 18.35% | |
Graham Net Nets |
0.03 | 0.02 | (0.01) | (0.08) | |
Graham Number |
0.00 | 0.00 | 0.00 | 3.19 | |
Earnings Yield |
(15.66%) | (11.94%) | (11.48%) | (12.56%) | |
Free Cash Flow Yield |
(17.74%) | (13.49%) | (11.35%) | (10.52%) | |
Revenue per Share |
0.79 | 0.74 | 0.82 | 0.93 | |
Operating CF per Share |
(0.80) | (0.57) | (0.34) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.80) | (0.57) | (0.34) | (0.30) | |
Cash per Share |
4.78 | 4.09 | 6.23 | 4.87 | |
Shareholders Equity per Share |
0.75 | 0.47 | 0.17 | (0.19) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.75 | 0.47 | 0.17 | (0.19) | |
Free Cash Flow |
(69.54) | (50.34) | (30.31) | (27.25) | |
Working Capital |
407.97 | 385.00 | 575.36 | 446.47 | |
Capital Expenditures |
(0.06) | — | (0.04) | 0.00 | |
Net Current Asset Value |
63.01 | 40.13 | (13.51) | (142.41) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
39.69 | 39.10 | 52.76 | 58.93 | |
Average Payables |
14.10 | 10.45 | 11.11 | 8.70 | |
Average Inventory |
16.56 | 19.81 | 25.43 | 32.19 | |
Average Assets |
627.26 | 556.69 | 649.90 | 622.23 | |
Average Common Equity |
176.38 | 128.34 | 86.26 | 49.13 |
Columns are period end dates · fundamentals updated 6 Nov 2026